Satellite Symposia

Array
(
    [0] => Array
        (
            [heading_text] => 8 November 2023
            [accordion_item] => Array
                (
                    [0] => Array
                        (
                            [title] => Array
                                (
                                    [text] => Fireside Chat: Asia-Pacific in Action, Revitalized emphasis on National Influenza vaccination Programs
                                    [thumbnail] => https://asianvaccine.com/wp-content/uploads/2023/08/Sanofi-logo-1-e1693366714963.jpg
                                )

                            [description] => 




 


Title



Fireside Chat: Asia-Pacific in Action, Revitalized emphasis on National Influenza vaccination Programs












Details		
Date: November 8, 2023


Time: 6:35pm to 7:20pm





 


 


 


 


 


 


 


 


 


Synopsis

 


Vaccine remains the most effective countermeasure against morbidity and mortality caused by influenza virus, but national programs and policies differ by region, financial capacity, and immunization strengths. Population ageing, socioeconomic, and political contexts contribute to the diversity of health system infrastructures.


Adult vaccination rates in the Asia-Pacific region are suboptimal, necessitating a strong commitment to improving adult vaccination rates. A life course approach to vaccination, concentrating on disease prevention and resolving barriers to vaccination, should be incorporated into health promotion strategies.


A collaborative approach with a renewed emphasis on redesigning, rebuilding, monitoring, and evaluating influenza immunization programs in the Asia Pacific can increase public receptivity and demand for adult immunization by increasing targeted communication for older adults and healthcare professionals, supporting multidisciplinary and cross-sectoral coordination, encouraging political commitment, and constructing robust data to inform policies and programs.


 


References:


1.       Seasonal influenza vaccines: an overview for decision-makers. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.


2.       El Guerche-Séblain, C., Caini, S., Paget, J. et al. Epidemiology and timing of seasonal influenza epidemics in the Asia-Pacific region, 2010–2017: implications for influenza vaccination programs. BMC Public Health 19, 331 (2019). https://doi.org/10.1186/s12889-019-6647-y


3.       Cowling, B.J., Caini, S., Chotpitayasunondh, T., Djauzi, S., Gatchalan, S.R., Huang, Q.S., Koul, P.A., Lee, P.I., Muttalif, A.R., Plotkin, S. Influenza in the Asia-Pacific region: Findings and recommendations from the Global Influenza Initiative. Vaccin 2017: 35(6), 856-864


4.       Kathleen F. Morales, David W. Brown,  et al,Seasonal influenza vaccination policies in the 194 WHO Member States: The evolution of globalinfluenza pandemic preparedness and the challenge of sustaining equitable vaccine access, Vaccine 2021, DOI: doi.org/10.1016/j.jvacx.2021.100097.


5.       Stancu Andra, Khan Anusheh, Barratt Jane, Driving the life course approach to vaccination through the lens of key global agendas. Frontiers in Aging,2023, DOI=10.3389/fragi.2023.1200397


6.       APEC Action Plan on Vaccination Across the Life Course





 


 


Objectives

Strengthen Regional and Country action towards Influenza Immunization Programs

To raise urgency on burden of influenza disease and its complications

To drive Stakeholder synergies to implement or enhance current influenza vaccination programs public settings

To facilitate best practice Sharing : Recommendations to Policies and Programs		




 


 


 


 


 


 


 


 


 


 


Faculty




Dr. Rontgene Solante, PH


Clinical Assistant Professor 1, Department of Medicine , College of Medicine, University of the East Ramon Magsaysay Memorial Medical Center


National President, Philippine College of Physicians


Convenor, Raise Coalition Philippine Foundation for Vaccination









Dr. Maria Wilda Silva, PH


Immunization Consultant, Unicef, Tonga


Past Department of Health National Immunization Program Manager Department of Health


Member, Philippine Foundation for Vaccination









Prof. Dr. Maw Pin Tan, MY


Professor of Geriatric Medicine at the University of Malaya


President of the Malaysian Society of Geriatric Medicine


Honorary General Secretary of the College of Physicians of Malaysia









Dr. Alex Richard Cook, SG


Vice Dean (Research) Vice Dean (Research) and Domain Leader (Biostatistics & Modelling), NUS Saw Swee Hock School of Public Health (Primary)


Associate Professor at the Department of Statistics and Applied Probability, NUS Yong Loo Lin School of Medicine, and the Program in Health Services and Systems Research at the Duke-NUS Graduate Medical School Singapore (Joint)






 


 


 


 


 


Schedule

Time
Description/Title










3 mins
Welcome Remarks and Introduction




 


 


 


40 mins



Fireside Chat


Topics

· Addressing the Problem: Current Status  of Influenza Disease and Surveillance in Asia Pacific


· Tailoring Programs: Designing Immunization Programs for Seasonal Influenza: Is there a Standard?


· Best Practice Sharing : Learning from the Regional Partners


· Call for Integration : Maximizing  public health programs  with  influenza  vaccination






2 mins
Final Remarks












                        )

                )

        )

    [1] => Array
        (
            [heading_text] => 10 November 2023
            [accordion_item] => Array
                (
                    [0] => Array
                        (
                            [title] => Array
                                (
                                    [text] => Novavax, from small biotech to the world stage. Development of a protein-based COVID-19 vaccine from Pandemic to Endemic use
                                    [thumbnail] => https://asianvaccine.com/wp-content/uploads/2023/09/WhatsApp-Image-2023-07-13-at-11.21.14-AM.jpeg
                                )

                            [description] => 




Title
Novavax, from small biotech to the world stage. Development of a protein-based COVID-19 vaccine from Pandemic to Endemic use.

ASVAC 2022		




Details
Date: 10 November

Time: 8:30am – 9:15am		




Synopsis
The Novavax Symposium will review the Clinical Development Programme of Novavax’s Covid19 vaccine (Nuvaxovid) including the latest development of the monovalent XBB1.5 vaccine, the latest paediatric data, an update of safety data,

and the Novavax future pipeline.		




Objectives
Inform participants of the Novavax clinical development program since the start of the COVID-19 pandemic.




Faculty

Professor Emeritus Lulu C. Bravo, MD, FPPS, FPSMID, FPIDSP, Philippines 


Lulu Bravo is a Professor Emeritus at the College of Medicine, University of the Philippines Manila. She is the former Vice Chancellor for Research and Executive Director of the National Institutes of Health, University of the

Philippines Manila (2005 – 2011) and current head of the Vaccine Study Group of the NIH – UP having done studies on vaccines and vaccine-preventable diseases throughout her professional career.


(Session chair) 






Dr. Seth Toback, MD, USA. 


Dr. Toback is currently a Senior Vice President of Medical Affairs at Novavax. He has worked in the pharmaceutical and biotechnology fields for the past ~20 years focusing on vaccines and therapeutics against respiratory viruses.

Prior to that he was in private practice pediatrics in Pittsburgh Pennsylvania close to where he trained at the Children’s Hospital of Pittsburgh. He is a board-certified Pediatrician with degrees from Carnegie-Mellon, Heinz

School of Public Policy and Management, Tufts University School of Medicine and McGill University.






Dr. Matthew Rousculp, PhD, MPH, USA 


Matthew is Vice President, RWE at Novavax (a biotech company committed to help address serious infectious diseases). He has over 20 years of industry experience in bio-pharma, with the majority of his experience in Global and U.S.

leadership roles in health economics and outcomes research. Matthew has also held various roles at Eli Lilly, MedImmune/AZ, GSK, and Takeda leading evidence generation across a wide portfolio as well as roles in market access

public policy, quality measures, and innovative financing policies. Matthew completed his studies at Rutgers University and The University of Alabama at Birmingham.





Schedule
Time
Description/Title





8:00am
Chairperson Introduction – Prof Emeritus Lulu C. Bravo
5 mins




8:05am
Background to the Novavax development program during the pandemic and an update of current data – Dr Seth Toback
20 mins




8:25am
Update on safety data and the Novavax pipeline – Dr Matthew Rousculp
15 mins




8:40am
Q & A moderated by Prof. Lulu
5 mins






                        )

                )

        )

)

8 November 2023

 

Title
Fireside Chat: Asia-Pacific in Action, Revitalized emphasis on National Influenza vaccination Programs

Details		 Date: November 8, 2023

Time: 6:35pm to 7:20pm
 

 

 

 

 

 

 

 

 

Synopsis

  

Vaccine remains the most effective countermeasure against morbidity and mortality caused by influenza virus, but national programs and policies differ by region, financial capacity, and immunization strengths. Population ageing, socioeconomic, and political contexts contribute to the diversity of health system infrastructures.

Adult vaccination rates in the Asia-Pacific region are suboptimal, necessitating a strong commitment to improving adult vaccination rates. A life course approach to vaccination, concentrating on disease prevention and resolving barriers to vaccination, should be incorporated into health promotion strategies.

A collaborative approach with a renewed emphasis on redesigning, rebuilding, monitoring, and evaluating influenza immunization programs in the Asia Pacific can increase public receptivity and demand for adult immunization by increasing targeted communication for older adults and healthcare professionals, supporting multidisciplinary and cross-sectoral coordination, encouraging political commitment, and constructing robust data to inform policies and programs.

 

References:

1.       Seasonal influenza vaccines: an overview for decision-makers. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.

2.       El Guerche-Séblain, C., Caini, S., Paget, J. et al. Epidemiology and timing of seasonal influenza epidemics in the Asia-Pacific region, 2010–2017: implications for influenza vaccination programs. BMC Public Health 19, 331 (2019). https://doi.org/10.1186/s12889-019-6647-y

3.       Cowling, B.J., Caini, S., Chotpitayasunondh, T., Djauzi, S., Gatchalan, S.R., Huang, Q.S., Koul, P.A., Lee, P.I., Muttalif, A.R., Plotkin, S. Influenza in the Asia-Pacific region: Findings and recommendations from the Global Influenza Initiative. Vaccin 2017: 35(6), 856-864

4.       Kathleen F. Morales, David W. Brown,  et al,Seasonal influenza vaccination policies in the 194 WHO Member States: The evolution of globalinfluenza pandemic preparedness and the challenge of sustaining equitable vaccine access, Vaccine 2021, DOI: doi.org/10.1016/j.jvacx.2021.100097.

5.       Stancu Andra, Khan Anusheh, Barratt Jane, Driving the life course approach to vaccination through the lens of key global agendas. Frontiers in Aging,2023, DOI=10.3389/fragi.2023.1200397

6.       APEC Action Plan on Vaccination Across the Life Course
 

 

Objectives

 Strengthen Regional and Country action towards Influenza Immunization Programs
To raise urgency on burden of influenza disease and its complications
To drive Stakeholder synergies to implement or enhance current influenza vaccination programs public settings
To facilitate best practice Sharing : Recommendations to Policies and Programs
 

 

 

 

 

 

 

 

 

 

Faculty

Dr. Rontgene Solante, PH

Clinical Assistant Professor 1, Department of Medicine , College of Medicine, University of the East Ramon Magsaysay Memorial Medical Center

National President, Philippine College of Physicians

Convenor, Raise Coalition Philippine Foundation for Vaccination

Dr. Maria Wilda Silva, PH

Immunization Consultant, Unicef, Tonga

Past Department of Health National Immunization Program Manager Department of Health

Member, Philippine Foundation for Vaccination

Prof. Dr. Maw Pin Tan, MY

Professor of Geriatric Medicine at the University of Malaya

President of the Malaysian Society of Geriatric Medicine

Honorary General Secretary of the College of Physicians of Malaysia

Dr. Alex Richard Cook, SG

Vice Dean (Research) Vice Dean (Research) and Domain Leader (Biostatistics & Modelling), NUS Saw Swee Hock School of Public Health (Primary)

Associate Professor at the Department of Statistics and Applied Probability, NUS Yong Loo Lin School of Medicine, and the Program in Health Services and Systems Research at the Duke-NUS Graduate Medical School Singapore (Joint)
 

 

 

 

 

Schedule

 Time Description/Title
3 mins Welcome Remarks and Introduction
 

 

 

40 mins

Fireside Chat

Topics
· Addressing the Problem: Current Status  of Influenza Disease and Surveillance in Asia Pacific

· Tailoring Programs: Designing Immunization Programs for Seasonal Influenza: Is there a Standard?

· Best Practice Sharing : Learning from the Regional Partners

· Call for Integration : Maximizing  public health programs  with  influenza  vaccination
2 mins Final Remarks

10 November 2023

Title Novavax, from small biotech to the world stage. Development of a protein-based COVID-19 vaccine from Pandemic to Endemic use.
ASVAC 2022
Details Date: 10 November
Time: 8:30am – 9:15am
Synopsis The Novavax Symposium will review the Clinical Development Programme of Novavax’s Covid19 vaccine (Nuvaxovid) including the latest development of the monovalent XBB1.5 vaccine, the latest paediatric data, an update of safety data,
and the Novavax future pipeline.
Objectives Inform participants of the Novavax clinical development program since the start of the COVID-19 pandemic.
Faculty Professor Emeritus Lulu C. Bravo, MD, FPPS, FPSMID, FPIDSP, Philippines

Lulu Bravo is a Professor Emeritus at the College of Medicine, University of the Philippines Manila. She is the former Vice Chancellor for Research and Executive Director of the National Institutes of Health, University of the
Philippines Manila (2005 – 2011) and current head of the Vaccine Study Group of the NIH – UP having done studies on vaccines and vaccine-preventable diseases throughout her professional career.

(Session chair)

Dr. Seth Toback, MD, USA.

Dr. Toback is currently a Senior Vice President of Medical Affairs at Novavax. He has worked in the pharmaceutical and biotechnology fields for the past ~20 years focusing on vaccines and therapeutics against respiratory viruses.
Prior to that he was in private practice pediatrics in Pittsburgh Pennsylvania close to where he trained at the Children’s Hospital of Pittsburgh. He is a board-certified Pediatrician with degrees from Carnegie-Mellon, Heinz
School of Public Policy and Management, Tufts University School of Medicine and McGill University.
Dr. Matthew Rousculp, PhD, MPH, USA

Matthew is Vice President, RWE at Novavax (a biotech company committed to help address serious infectious diseases). He has over 20 years of industry experience in bio-pharma, with the majority of his experience in Global and U.S.
leadership roles in health economics and outcomes research. Matthew has also held various roles at Eli Lilly, MedImmune/AZ, GSK, and Takeda leading evidence generation across a wide portfolio as well as roles in market access
public policy, quality measures, and innovative financing policies. Matthew completed his studies at Rutgers University and The University of Alabama at Birmingham.
Schedule Time Description/Title
8:00am Chairperson Introduction – Prof Emeritus Lulu C. Bravo 5 mins
8:05am Background to the Novavax development program during the pandemic and an update of current data – Dr Seth Toback 20 mins
8:25am Update on safety data and the Novavax pipeline – Dr Matthew Rousculp 15 mins
8:40am Q & A moderated by Prof. Lulu 5 mins